Nolwenn Le Stang

Nolwenn Le Stang

Auto-generated profile, based on publicly available information

Nolwenn Le Stang

Department of Pathology, MESOPATH-MESOBANK, Centre León Bérard, Lyon, France

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PCPierre Courtiol
Pierre Courtiol
CMCharles Maussion
Charles Maussion
MMMatahi Moarii
Matahi Moarii
EPElodie Pronier
Elodie Pronier
SPSamuel Pilcer
Samuel Pilcer
TCThomas Clozel
Thomas Clozel

1 June 2008 in Revue D'Épidémiologie Et de Santé Publique
Verified
Journal Article
Closed access
ABAurelien Belot
Aurelien Belot
PGpascale grosclaude
pascale grosclaude
NBN. Bossard
N. Bossard
EJE. Jougla
E. Jougla
EBE. Benhamou
E. Benhamou
MVM. Velten
M. Velten

20 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
NAN. Alcala
N. Alcala
NLN. Leblay
N. Leblay
AGA. A. G. Gabriel
A. A. G. Gabriel
LML. Mangiante
L. Mangiante
DHDavid Hervás
David Hervás
LFL. Fernandez-Cuesta
L. Fernandez-Cuesta
The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value ofOTPexpression levels for the prognosis and diagnosis of these diseases, and we unveil the group of supra-carcinoids. This group comprises samples with carcinoid-like morphology yet the molecular and clinical features of the deadly LCNEC, further supporting the previously proposed molecular link between the low- and high-grade lung neuroendocrine neoplasms.

16 January 2018 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
JAJ. Adam
J. Adam
NSN. Le Stang
N. Le Stang
IRI. Rouquette
I. Rouquette
ACA. Cazes
A. Cazes
CBC. Badoual
C. Badoual
SLS. Lantuéjoul
S. Lantuéjoul
Various programed death ligand 1 (PD-L1) immunohistochemistry (IHC) assays have been developed and used in clinical trials in association with different drugs. In order to harmonize and make PD-L1 testing in non-small-cell lung cancer (NSCLC) widely available, we conducted a multicenter study comparing PD-L1 standardized assays and laboratory-developed tests (LDTs). IHC with five anti-PD-L1 monoclonal antibodies (28-8, 22C3, E1L3N, SP142 and SP263) was performed concomitantly on 41 NSCLC surgical specimens in 7 centers using Dako Autostainer Link 48 (3 centers), Leica Bond (2 centers) or Ventana BenchMark Ultra (2 centers) platforms. For each matching platform, 22C3, 28-8 and SP263 assays were performed. For nonmatching platforms and other antibodies, LDTs were developed in each center. A total of 35 stainings were performed for each case across different platforms and antibodies. PD-L1 staining was assessed in tumor cells and immune cells by seven trained thoracic pathologists. For statistical analysis, 1%, 50% and 1%, 5%, 10% expression thresholds were used for tumor cells and immune cells, respectively. 28-8, 22C3 and SP263 assays were highly concordant for tumor cells staining across the five Dako or Ventana platforms. Among 27 LDTs developed in 7 centers on Dako, Ventana and Leica platforms, 14 (51.8%) demonstrated similar concordance when compared with reference assays for tumor cell staining. Clone SP263 achieved the highest concordance rate across all platforms. Lower concordance was observed for immune cells staining when using a four categories scale. 28-8, 22C3 and SP263 assays had close analytical performance for tumor cell staining across seven centers. Some LDTs on Dako, Ventana and Leica platforms achieved similar concordance, but caution is warranted for their validation. These LDTs will be further validated in order to provide recommendations for the use of assays and LDT for PD-L1 testing in NSCLC.

1 February 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
DCDavid B. Chapel
David B. Chapel
JSJefree J. Schulte
Jefree J. Schulte
KBKyra Berg
Kyra Berg
ACAndrew Churg
Andrew Churg
SDSanja Dacic
Sanja Dacic
AHAliya N. Husain
Aliya N. Husain

1 April 2018 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
LRLauren E Rosen
Lauren E Rosen
TKTheodore Karrison
Theodore Karrison
VAVijayalakshmi Ananthanarayanan
Vijayalakshmi Ananthanarayanan
AGAlexander J Gallan
Alexander J Gallan
PAPrasad S Adusumilli
Prasad S Adusumilli
AHAliya N Husain
Aliya N Husain